Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism

Yu, Haozhe; Liu, Zhuohui; Lu, Jie; Yang, Xinying; Yan, Xinxin; Mi, Yuhong; Liu, Hua; Li, Yulin; Jing, Zhi‐Cheng; Du, Jie

doi:10.1007/s12012-019-09525-w

Cited by 5 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dysregulation of markers such as calprotectin (S100A8/A9), 16,17 cystatin C (CST3), 18,19 and lipocalin-2 (LCN2) 20,21 is linked with cardiovascular complications including vascular inflammation and VTE and tissue injury. S100A8/A9 is secreted from myeloid cells in response to inflammatory reactions and regulates the pathogenesis of cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19

Gupta

Al-Tamimi

Halwani

et al. 2022

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Severe coronavirus (SARS-COV-2) infection often leads to systemic inflammation accompanied by cardiovascular complications including venous thromboembolism (VTE). However, it is largely undefined if inflammatory markers such as lipocalin-2 (LNC2), calprotectin (S100A8/A9), and cystatin C (CST3), previously linked with VTE, play roles in cardiovascular complications and advancement of COVID-19 severity. To investigate the same, hospitalized moderate and severe (presented pneumonia and required intensive care) COVID-19 patients were recruited. The levels of plasma LNC2, S100A8/A9, CST3, myoglobin, and cardiac Troponin I (cTnI) were assessed through enzyme-linked immunosorbent assay (ELISA). The investigation revealed a significantly upregulated level of plasma LNC2 at the moderate stage of SARS-CoV-2 infection. In contrast, the levels of S100A8/A9 and CST3 in moderate patients were comparable to healthy controls; however, a profound induction was observed only in severe COVID-19 patients. The tissue injury marker myoglobin was unchanged in moderate patients; however, a significantly elevated level was observed in the critically ill COVID-19 patients. In contrast, cTnI level was unchanged both in moderate and severe patients. Analysis revealed a positive correlation between the levels of S100A8/A9 and CST3 with myoglobin in COVID-19. In silico analysis predicted interactions of S100A8/A9 with toll-like receptor 4 (TLR-4), MyD88 LY96, and LCN2 with several other inflammatory mediators including MMP2, MMP9, TIMP1, and interleukins (IL-6, IL-17A, and IL-10). In summary, early induction of LCN2 likely plays a role in advancing the COVID-19 severity. A positive correlation of S100A8/A9 and CST3 with myoglobin suggests that these proteins may serve as predictive biomarkers for thromboembolism and tissue injury in COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19

Gupta

Al-Tamimi

Halwani

et al. 2022

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Song et al have reported a case of obstructive uropathy caused by a 20-cm-sized hematoma anterior to the bladder in Retzius space following postpartum pulmonary embolism [ 59 ]. Recently, elevated plasma lipocalin-2 levels have been a promising biomarker in predicting long-term major adverse events among normotensive patients with APE for risk stratification in the intermediate-risk group [ 60 ]. Most importantly, multidisciplinary management with interhospital transfer and advanced armamentarium is necessarily required to control the coagulopathy profile, prevent multi-organ dysfunction, and reduce significant mortality [ 23 , 61 ].…”

Section: Discussionmentioning

confidence: 99%

Successfully conservative management of the uterus in acute pulmonary embolism during cesarean section for placenta previa: a case report from Tu Du Hospital, Vietnam and literature review

Vuong,

Pham,

Bui

et al. 2024

Int J Emerg Med

View full text Add to dashboard Cite

Background Cardiopulmonary collapse is a catastrophic event in cesarean section, which leads to adverse outcomes for both the mother and the fetus. Pulmonary embolism is one of the rare etiologies of this entity. We herein reported the successful management of acute embolism pulmonary associated with cesarean delivery on a healthy pregnant woman at our tertiary referral hospital. Case presentation A full-term pregnant woman hospitalized for planned cesarean delivery due to placenta previa without cardiorespiratory diseases. She was scheduled uneventfully for a planned cesarean section. After placental delivery, the patient spontaneously fell into cardiopulmonary collapse and her vital signs deteriorated rapidly. The obstetricians promptly completed the cesarean section and performed all procedures to prevent the PPH and preserve the uterus. At the same time, the anesthesiologists continued to carry out advanced heart-lung resuscitation in order to control her vital signs. After surgery, the multidisciplinary team assessed the patient and found a thrombus in her pulmonary circulation. Therefore, the patient was managed with therapeutic anticoagulation. The patient recovered in good clinical condition and was discharged after 2 weeks without any complications. Conclusions The diagnosis of acute pulmonary embolism is extremely difficult due to uncommon occurrence, sudden onset, and non-specific presentation. Awareness of this life-threatening pathology during cesarean delivery should be raised. Interdisciplinary assessment must be essentially established in this life-threatening condition. After the whole conventional management, uterine conservation may be acceptable where applicable. Further data is required to encourage this finding.

show abstract

“…Interestingly, there is a negative correlation between TRAIL and hsCRP, which provides further support for the protective role of TRAIL in the development of atherosclerosis and acute coronary disease [32]. [33][34][35], and several studies investigated the prognostic value of biomarkers on risk stratification (e.g., Copeptin and Lipocalin-2) [16,19]. Due to the relatively limited performance of the 2019 ESC algorithm, we developed a novel and simple stepwise biomarker-based strategy using TRAIL and hs-cTnI.…”

Section: The Potential Role Of Trail In Pementioning

confidence: 91%

“…Patients with acute PE were objectively confirmed by computed tomography pulmonary angiography (CTPA) and a ventilation-perfusion lung scan. The exclusion criteria were the following: [14][15][16] (1) hemodynamic instability: (A) cardiac arrest: cardiopulmonary resuscitation required; (B) obstructive shock: systolic blood pressure (BP) < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status and end-organ hypoperfusion (altered mental status; cold, clammy skin; oliguria/anuria); (C) persistent hypotension: systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolaemia, or sepsis; (2) recurrence of PE; (3) chronic thromboembolic pulmonary hypertension; (4) life expectancy <3 months (i.e., the end stage of diseases);…”

Section: Selection Of Participantsmentioning

confidence: 99%

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

Rong²,

Yang³

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is associated with poor prognosis in cardiovascular diseases. However, the predictive value of TRAIL for the short-term outcome and risk stratification of acute pulmonary embolism (PE) remains unknown. Methods: This study prospectively included 151 normotensive patients with acute PE. The study outcome was a composite of 30-day adverse events, defined as PE-related death, shock, mechanical ventilation, cardiopulmonary resuscitation, and major bleeding. Results: Overall, nine of 151 (6.0%) patients experienced 30-day adverse composite events. Multivariable logistic regression showed that TRAIL was an independent predictor of study outcome (OR 0.19 per SD; 95% CI 0.04–0.90). An ROC curve revealed that TRAIL’s area under the curve (AUC) was 0.83 (95% CI 0.76–0.88). The optimal cut-off value for TRAIL was 18 pg/mL, with a sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood ratio, and negative likelihood ratio of 89%, 69%, 99%, 15%, 2.87, and 0.16, respectively. Compared with the risk stratification algorithm outlined in the 2019 ESC guidelines, our biomarker-based risk stratification strategy (combining TRAIL and hs-cTnI) has a similar risk classification effect. Conclusion: Reduced plasma TRAIL levels predict short-term adverse events in normotensive patients with acute PE. The combination of the 2019 ESC algorithm and TRAIL aids risk stratification in normotensive patients with acute PE.

show abstract

Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism

Cited by 5 publications

References 34 publications

Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19

Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19

Successfully conservative management of the uterus in acute pulmonary embolism during cesarean section for placenta previa: a case report from Tu Du Hospital, Vietnam and literature review

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

Contact Info

Product

Resources

About